Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Cost of Revenue: 2022-2025

Historic Cost of Revenue for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to $3.2 million.

  • InMed Pharmaceuticals' Cost of Revenue fell 7.04% to $716,962 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 6.07%. This contributed to the annual value of $3.2 million for FY2025, which is 7.46% down from last year.
  • InMed Pharmaceuticals' Cost of Revenue amounted to $3.2 million in FY2025, which was down 7.46% from $3.5 million recorded in FY2024.
  • In the past 5 years, InMed Pharmaceuticals' Cost of Revenue registered a high of $3.5 million during FY2024, and its lowest value of $545,889 during FY2022.
  • Moreover, its 3-year median value for Cost of Revenue was $3.2 million (2025), whereas its average is $3.2 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first soared by 400.56% in 2023, then declined by 7.46% in 2025.
  • InMed Pharmaceuticals' Cost of Revenue (Yearly) stood at $545,889 in 2022, then surged by 400.56% to $2.7 million in 2023, then grew by 27.97% to $3.5 million in 2024, then decreased by 7.46% to $3.2 million in 2025.